Ask most people how to judge a research peptide and they’ll point to one number: purity. 98%, 99%, 99.5% — higher is better, end of story. But that single figure, printed on a certificate of analysis, quietly leaves out the most interesting question. If a peptide is 98% pure, what makes up the other 2%? And how do you know the 98% is even the molecule you think it is?
Where Impurities Come From
Peptides are built one amino acid at a time, most often by solid-phase peptide synthesis (SPPS). Each residue is added through a coupling reaction, then a protecting group is removed, and the cycle repeats. It’s an elegant process — but with dozens of sequential steps, small failures accumulate. The impurities that show up in the final material generally trace back to a handful of predictable sources:
- Incomplete reactions: when a coupling step doesn’t run to completion, some chains carry on without that residue.
- Deletion sequences: a missing amino acid produces a peptide that is one residue short — often nearly identical in mass and behavior to the target, which is exactly what makes it hard to spot.
- Side products: extra reactions, incomplete deprotection, or truncated chains that terminate early.
- Degradation over time: oxidation, deamidation, hydrolysis, or aggregation that occurs after synthesis, especially with poor storage.
Each of these leaves a different fingerprint, and each can affect experimental results in a different way.
Why the Percentage Alone Falls Short
Consider two vials, both labeled 98% pure. In one, the remaining 2% is residual solvent and water — inert background. In the other, that 2% is a deletion sequence missing a single critical residue, a molecule structurally close enough to bind the same targets but behave differently. From the headline number, these two materials look identical. In the lab, they are not. An impurity that is biologically active — or that competes with the target peptide — can quietly skew binding assays, cell-based readouts, or animal-study data in preclinical research.
This is why analytical chemists distinguish between purity and the impurity profile. Purity tells you how much. The impurity profile tells you what, and that’s the part that determines whether your “contaminant” is noise or a confound.
Identity: Proving It’s the Right Molecule
Purity also assumes you already know what the main peak is. Confirming identity is a separate step. High-performance liquid chromatography (HPLC) separates the components of a sample and quantifies them, giving the purity figure. Mass spectrometry (MS) then measures the molecular weight of the target peak, verifying that the dominant species actually matches the intended sequence. Read together, HPLC and MS answer two different questions — how pure and is it the right compound — and neither substitutes for the other. Good documentation presents both, along with the method used, so a researcher can interpret the material rather than take a number on faith.
Why This Matters for Researchers
Reproducibility depends on knowing what you’re actually working with. An unlabeled active impurity, a batch that degraded in transit, or an unverified identity can all introduce variables that no amount of careful experimental design will control for. Transparent characterization — a real chromatogram, a mass-spec confirmation, a disclosed impurity profile — turns a vial from a black box into a defined research input.
OpenLabs supplies peptides strictly for research use only; nothing here is intended as medical, diagnostic, or human-use guidance. But the principle is universal to good preclinical science: the researchers who get cleaner, more reproducible data are the ones who care what’s in the vial — not just the percentage on the label, but everything the label leaves out.